Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

TRACERx preoperative ctDNA was detected in 81% of lung adenocarcinomas with an ultrasensitive assay

A Nature Medicine paper published January 13, 2025, tested preoperative plasma from 171 TRACERx patients and detected ctDNA in 76 of 94 lung adenocarcinomas (81%), including 16 of 28 with stage I adenocarcinoma, and in 77 of 77 non-adenocarcinoma non-small cell lung cancers.

Nature Medicine